Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 150-153, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-202462
ABSTRACT
Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic agent since 1997, but survival benefit is not satisfactory. Recent clinical study proved that several new combination chemotherapy regimens are superior to gemcitabine single chemotherapy and extended overall survival. However, its prognosis still remains grim. Current research is taking a multidirectional approach in the hope of developing more effective treatments. This article reviews the major clinical trial data that is the basis for the current chemotherapy regimens used as first- and second-line treatments for advanced pancreatic adenocarcinoma. This article also reviews the current ongoing clinical trials, which include the use of molecular targeting agents and immune therapies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Pancreáticas
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Desoxicitidina
/
Inhibidores de Proteínas Quinasas
/
Inmunoterapia
/
Antimetabolitos Antineoplásicos
/
Antineoplásicos
Límite:
Humanos
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS